Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies
Open Access
- 28 January 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 12, 824788
- https://doi.org/10.3389/fcimb.2022.824788
Abstract
The gram-positive bacterium Streptococcus pneumoniae is a leading cause of pneumonia, otitis media, septicemia, and meningitis in children and adults. Current prevention and treatment efforts are primarily pneumococcal conjugate vaccines that target the bacterial capsule polysaccharide, as well as antibiotics for pathogen clearance. While these methods have been enormously effective at disease prevention and treatment, there has been an emergence of non-vaccine serotypes, termed serotype replacement, and increasing antibiotic resistance among these serotypes. To combat S. pneumoniae, the immune system must deploy an arsenal of antimicrobial functions. However, S. pneumoniae has evolved a repertoire of evasion techniques and is able to modulate the host immune system. Antibodies are a key component of pneumococcal immunity, targeting both the capsule polysaccharide and protein antigens on the surface of the bacterium. These antibodies have been shown to play a variety of roles including increasing opsonophagocytic activity, enzymatic and toxin neutralization, reducing bacterial adherence, and altering bacterial gene expression. In this review, we describe targets of anti-pneumococcal antibodies and describe antibody functions and effectiveness against S. pneumoniae.Funding Information
- American Lung Association
This publication has 205 references indexed in Scilit:
- Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind TrialClinical Infectious Diseases, 2013
- The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of PneumococciIn VitroClinical and Vaccine Immunology, 2012
- Nasopharyngeal Colonization Elicits Antibody Responses to Staphylococcal and Pneumococcal Proteins That Are Not Associated with a Reduced Risk of Subsequent CarriageInfection and Immunity, 2012
- Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humansVaccine, 2012
- Immunization with Pneumolysin Protects Against Both Retinal and Global Damage Caused byStreptococcus pneumoniaeEndophthalmitisJournal of Ocular Pharmacology and Therapeutics, 2010
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- The surface-anchored NanA protein promotes pneumococcal brain endothelial cell invasionThe Journal of Experimental Medicine, 2009
- Characterization of Protective Mucosal and Systemic Immune Responses Elicited by Pneumococcal Surface Protein PspA and PspC Nasal Vaccines against a Respiratory Pneumococcal Challenge in MiceClinical and Vaccine Immunology, 2009
- A Human Monoclonal Immunoglobulin M Reduces Bacteremia and Inflammation in a Mouse Model of Systemic Pneumococcal InfectionClinical and Vaccine Immunology, 2007
- Streptococcus pneumoniae colonisation: the key to pneumococcal diseaseThe Lancet Infectious Diseases, 2004